drugset / Trial / NCT00494481

E3 Breast Cancer Taxotere Combination

NCT00494481

Phase 2 Completed 64 enrolled Genzyme, a Sanofi Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology

Timeline

Start
2006-01
Primary completion
2007-06
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vandetanib Small molecule Oral
Background Docetaxel Small molecule Intravenous